Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Ovarian Neoplasms × taxane × Clear all

Phase

Phase 3 2 Phase NA 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 5 Triple Negative Breast Neoplasms 4 Lung Neoplasms 2 Fallopian Tube Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 HER2-negative Breast Cancer 1 Gastric Adenocarcinoma 1 Carcinoma, Small Cell 1 Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 115 Carboplatin 115 Bevacizumab 76 Gemcitabine 38 pembrolizumab 36 olaparib 32 Cisplatin 27 Docetaxel 26 Cyclophosphamide 26 niraparib 25 liposomal doxorubicin 23 Topotecan 22 Etoposide 17 Doxorubicin 15 Taxes 13 apatinib 12 Letrozole 12 Immunoglobulin G 11 Filgrastim 11 Drug Therapy 11 Disulfides 11 Albumin-Bound Paclitaxel 11 fludarabine 10 fluzoparib 9 Biopsy 9 durvalumab 8 Specimen Handling 8 Nivolumab 8 Magnetic Resonance Spectroscopy 8 Cytoreduction Surgical Procedures 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01669226 2016-12-19

AICE

Shanghai Gynecologic Oncology Group

Phase 2 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡